<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03221569</url>
  </required_header>
  <id_info>
    <org_study_id>779354-2</org_study_id>
    <nct_id>NCT03221569</nct_id>
  </id_info>
  <brief_title>Ketamine v. Ketorolac for Management of Generalized Tension Type Headache</brief_title>
  <official_title>Ketamine v. Ketorolac for Management of Generalized Tension Type Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Brooklyn Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Brooklyn Hospital Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of the study is that sub-dissociative dose ketamine will prove to be superior
      to or as standard therapy, ketorolac, in the treatment of acute tension type headache (TTH)
      as measured by the 10 point Numerical Rating Scale (NRS. The aim of the study is to compare
      the safety &amp; efficacy of intravenous sub-dissociative dose ketamine versus ketorolac for
      acute treatment of migraines in the Emergency Department (ED) The primary endpoints are:
      Patient perception of pain as described by the use the Numerical Rating Scale (NRS) at 30
      minutes.

      The secondary endpoints are: Frequency and mean dose of rescue/additional doses of therapy at
      15, 30, 45, 60, 75, 90 min, Number of emergency department re-visits for acute migraine one
      month post discharge, incidence of dissociative effects (characterized by hallucination,
      disorientation, confusion, agitation, delirium, dreams) during study period, incidence of
      nausea, vomiting, or worsening headache, Incidence of bad taste, Incidence of burning
      sensations in the nostrils, incidence of hypertension, time to patient discharge from the
      initiation of study medication/placebo, patient satisfaction of pain control based on a
      Likert Scale.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a &quot;double-dummy&quot; study in that there will be no placebo only arm. Medications
      will be administered in a double blind randomized fashion. Patients would be enrolled in Arm
      A or Arm B depending upon the initial randomization. Arm A would include 0.3 mg/kg ketamine
      into a 100 cc normal saline IV bag and normal saline injection (1ml) while Arm B would
      receive 100cc of normal saline and 30mg of ketorolac intravenously.

      An order would be placed by the medical resident, medical attending, a study investigator who
      is a physician, or a pharmacist under the permission of the attending physician into
      Allscripts for a study intervention. Upon receiving the order in Allscripts, the order would
      be verified by the pharmacy. All medications will be prepared in pharmacy, which will
      maintain a master list of contents of each sealed envelope. Once notified of which envelope
      has been pulled, the pharmacist will prepare either arm. ED personnel will obtain the
      infusion preparation from pharmacy. It will be labeled for the patient, with study number,
      but without other identifying marks. When the study medication is picked up, pharmacy will
      open the sealed envelope to confirm which medication arm was prepared in order to internally
      verify the correct preparation. The nurse assigned to the patient would administer the
      intervention. A research associate or a study investigator would approach the patient to
      assess and record primary outcomes, secondary outcomes at designed time intervals. The data
      will be recorded on the data collection instrument. If additional medication is requested by
      the patient, the orders would be placed by the medical resident or attending who are assigned
      to the patient in the ED. Upon completion of the treatment portion of the study, patients
      will be asked of the participant's satisfaction with therapy. Only the patient who signed the
      consent form will be allowed to answer the questions.

      All data retrieved from the paper data collection sheets will be transcribed into an
      encrypted and password protected electronic database by the research associate. All patient
      identifiers would be de-identified in the database. All participants would be assigned a
      study participant number.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Anticipated">February 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm A would include 0.3mg/kg intravenous piggyback ketamine and 1cc normal saline as placebo via intravenous push while Arm B would receive 50ml normal saline and ketorolac 30mg.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Aside from primary investigator (B.Sin) and pharmacist procuring the study interventions, blinding will be applied to patient, physicians, nurses, research associates responsible for collect data and also the independent biostatistician responsible for evaluating the data. Patients will be randomized to receive study numbers that corresponds to treatment arms.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain scores</measure>
    <time_frame>At 30 minutes after initiation of study intervention</time_frame>
    <description>10 point number rating scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>throughout study period (105 mins)</time_frame>
    <description>adverse events reported in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean dose of rescue analgesia required</measure>
    <time_frame>throughout study period (105 minutess)</time_frame>
    <description>dose of rescue analgesia required in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay</measure>
    <time_frame>throughout study period (105 minutes)</time_frame>
    <description>median ED length of stay in each group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Intravenous ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm will include 0.3 mg/kg intravenous piggyback ketamine over 10 minutes for 1 dose and a 1ml normal saline placebo via intravenous push</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketorolac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm will include 30mg ketorolac intravenous push and 50ml normal saline over 10 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous ketamine</intervention_name>
    <description>0.3mg/kg IVPB over 15 minutes</description>
    <arm_group_label>Intravenous ketamine</arm_group_label>
    <other_name>ketamine intravenous</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>as active comparator, will be administered together with metoclopramide in one normal saline 50ml bag</description>
    <arm_group_label>ketorolac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Will be given as 50ml intravenous bag as placebo for double-blinding purposes in patients who will also receive intranasal ketamine.
Will be prepared in intranasal syringe for double blinding purposes for patients who are randomized to receive intranasal ketamine.</description>
    <arm_group_label>Intravenous ketamine</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>1ml intravenous push as placebo for double-blinding purposes</description>
    <arm_group_label>ketorolac</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The inclusion criteria are: Patients 18-65 years old who provides informed consent and
             presents to the ED with an acute tension type headache (TTH), as classified by meeting
             the following:

               1. Have at least 10 episodes of headache occurring on average less than 12 days per
                  year AND Fullfuling B-D B. Lasting 30mins to 7 days C. At least 2 of the
                  following 4 criteria

               1. bilateral location

               2. pressing/tightening (non-pulsating)

               3. mild or moderate

               4. not aggravated by routine physical activity such as walking or climbing stairs D.
                  Both of the following

               1. no nausea/vomiting

               2. No more than one of photophobia or phonophobia

        Exclusion Criteria: Non migraine primary headache disorder or unclassifiable, previous
        enrollment in study, fever &gt;100.3, Patients with suspected secondary headache disorder such
        as SAH or sinusitis, performance of lumbar puncture or potential need for LP, Severe
        hypertension (â‰¥180/100), History of CAD or hypertension, presence of/suspected for
        traumatic head injury in the past 30 days with or without loss of consciousness, Presence
        of/suspected for myocardial ischemia, presence of/suspected for alcohol intoxication,
        Hemodynamic instability, history of psychiatric disorders, known or suspected pregnancy or
        breast feeding, allergy to ketamine, ketorolac, previous enrollment in the study, patients
        with language barriers, refusal to provide consent to receive intravenous therapy, reported
        illicit drug use within the past 5 days, patients weighing over 100kg
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Billy Sin, PharmD</last_name>
    <phone>718-250-5000</phone>
    <phone_ext>2450</phone_ext>
    <email>bsin@tbh.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Brooklyn Hospital Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Billy W Sin, Pharm.D.</last_name>
      <phone>718-250-6250</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 17, 2017</study_first_submitted>
  <study_first_submitted_qc>July 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>July 5, 2018</last_update_submitted>
  <last_update_submitted_qc>July 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Brooklyn Hospital Center</investigator_affiliation>
    <investigator_full_name>Billy Sin</investigator_full_name>
    <investigator_title>Director, Emergency Medicine Clinical Research Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tension-Type Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

